KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Non Operating Income data on record, last reported at $214.6 million in Q4 2025.

  • For Q4 2025, Non Operating Income rose 168.36% year-over-year to $214.6 million; the TTM value through Dec 2025 reached $16.5 million, up 103.6%, while the annual FY2025 figure was $16.5 million, 105.43% up from the prior year.
  • Non Operating Income reached $214.6 million in Q4 2025 per AMRX's latest filing, up from -$75.6 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $214.6 million in Q4 2025 and bottomed at -$313.9 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$45.7 million, with a median of -$38.1 million recorded in 2022.
  • The widest YoY moves for Non Operating Income: up 339.29% in 2023, down 7483.49% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$130.0 million in 2021, then soared by 102.62% to $3.4 million in 2022, then tumbled by 7483.49% to -$251.3 million in 2023, then fell by 24.95% to -$313.9 million in 2024, then surged by 168.36% to $214.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $214.6 million in Q4 2025, -$75.6 million in Q3 2025, and -$123.0 million in Q2 2025.